Huons and Humedix have joined hands to maximize group synergy with the successful launch of LIZTOX in South Korea.
Huons announced that the signing ceremony for a joint sales agreement for LIZTOX in South Korea was held between Huons CEO Um Ki-an and Humedix CEO Chung Ku-wan, at its headquarters in Pangyo on May 22.
Huons holds exclusive domestic and foreign sales rights for Huons Global's botulinum toxin "LIZTOX," and based on this, it signed the main agreement with Humedix.
On the signing of the main agreement, Huons and Humedix agreed that it is a strategic decision that can respond to the fierce local botulinum toxin market and create a strong synergy for the group as a whole, prior to the launch of LIZTOX in Korea.
Huons is planning to focus on clinical and licensing items based on large-scale export deals with countries in Europe, China and Latin America to accelerate its efforts to tap into the global botulinum toxin market.
"We have signed an agreement with Humedix, which has a strong presence as an esthetic company, to win a speedy recognition of LIZTOX in the market," said Huons CEO Um.
Meanwhile, Humedix CEO Chung said, "With this agreement, Humedix has not only secured a strong growth momentum, called LIZTOX, but is also able to make stable sales in conjunction with its various products. We will reorganize the esthetic market based on a systematic esthetic portfolio."
LIZTOX is a self-developed botulinum toxin by Huons Global. It entered overseas markets in October 2016 under the name of the item "Hutox," and acquired an item license in April this year in Korea and is set to be released in June.
